^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ALLO-605

    i
    Other names: ALLO-605 , ALLO-605 TurboCAR, ALLO605, ALLO 605
    Company:
    Allogene Therap, Cellectis
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    5ms
    Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=6, Terminated, Allogene Therapeutics | N=136 --> 6 | Trial completion date: Jul 2025 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Oct 2023; Terminated (Halted Prematurely)
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • ALLO-605 • ALLO-647
    4years
    [VIRTUAL] Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar TTM Cell Therapy for the Treatment of Multiple Myeloma (ASH 2020)
    First, we tested the ability of a CD20-based off-switch incorporated within the CAR to sensitize cells to rituximab and found effective depletion of BCMA TurboCAR T™ cells by complement or effector cells in vitro and in vivo in the presence of the antibody. In addition, we confirmed rapid inhibition of BCMA TurboCAR T™ cells by the protein tyrosine kinase inhibitor dasatinib, which has been shown to interfere with LCK activity. The prolonged persistence and antitumor responses seen in preclinical models along with a favorable safety profile of BCMA TurboCAR™ T cells support clinical investigation of ALLO-605 in relapsed or refractory multiple myeloma.
    Preclinical • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • MPL (MPL Proto-Oncogene, Thrombopoietin Receptor)
    |
    dasatinib • Rituxan (rituximab) • ALLO-605